Achieve Life Sciences

Business news, market intelligence, and global industry analysis.

The Latest

Netmarble Corporation bets on staged rollout to de-risk The Seven Deadly Sins: Origin open-world expansion

The real reason Netmarble is launching The Seven Deadly Sins: Origin in phases

Longeveron Inc. appoints Stephen H. Willard as CEO ahead of pivotal Phase 2b stem cell data

Philadelphia jury orders Johnson & Johnson to pay $250,000 in talc powder lawsuit

Representative image showing the intersection of financial performance and cancer diagnostics, reflecting Exact Sciences’ record 2025 results and its pending acquisition by Abbott Laboratories.

Exact Sciences (NASDAQ: EXAS) earnings show why Abbott moved now on a $21bn diagnostics acquisition

Hunterbrook Capital backs Achieve Life Sciences as FDA decision nears for cytisinicline

Hunterbrook Capital discloses a position in Achieve Life Sciences, citing cytisinicline’s potential to disrupt the smoking cessation market ahead of FDA review.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

December 31, 2025